BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

Novartis’ PD-1 misses in melanoma comboNovartis AG (NYSE:NVS; SIX:NOVN) said spartalizumab missed the primary endpoint of the Phase III COMBI-i trial in patients with untreated, unresectable BRAF V600-mutant cutaneous melanoma. The PD-1 inhibitor, in combination...
BioCentury | Jun 26, 2020
Distillery Therapeutics

MAP3K7, IL18R1 as targets in obesity-related cerebrovascular dysfunction

DISEASE CATEGORY: Endocrine/metabolic; neurology INDICATION: Obesity; stroke Inhibiting MAP3K7 or the IL-18 receptor subunit IL18R1 could treat obesity-associated cerebrovascular dysfunction. In cultured rat aortic endothelial cells, an siRNA against IL18R1 increased levels of phosphorylated NOS3,...
BioCentury | May 26, 2020
Distillery Therapeutics

Boosting Tnip3-mediated inhibition of MAP3K7 for non-alcoholic steatohepatitis

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Promoting the expression of Tnip3, which inhibits inflammation, and its prevention of MAP3K7 activation could treat NASH. Hepatic levels of Tnip3 protein and mRNA were lower in NASH...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 13, 2020
Regulation

FDA says cancer still a priority as it approves AZ’s Koselugo, a first for nerve tumors

With the approval of the first therapy for a rare pediatric cancer Friday, FDA is assuring cancer patients that getting treatments into their hands is still a priority for the agency during the COVID-19 pandemic....
BioCentury | Nov 16, 2019
Company News

Nov. 15 Company Quick Takes: Qiagen continues climb after confirming takeout offers; plus Fetroja, selumetinib, PharmAbcine, semaglutide

Qiagen confirms acquisition interest Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Friday it is reviewing its strategic alternatives after receiving several “non-binding indications of interest for the acquisition” of the diagnostics company. Since acquisition rumors emerged Wednesday,...
BioCentury | Sep 19, 2019
Distillery Therapeutics

DLK identified as target for Fragile X syndrome

DISEASE CATEGORY: Neurology INDICATION: Fragile X syndrome Inhibiting DLK, a mediator of neuronal injury responses, could treat Fragile X syndrome. In fruit flies with the disease, systemic DLK knockout or a tool compound DLK inhibitor...
BioCentury | Jul 1, 2019
Company News

Long wait cost Pfizer until BEACON data clinched Array deal

By waiting for a crucial clinical readout that arrived in May 2019, Pfizer watched Array's stock price climb for two years, eventually paying a takeout price that was well over four times the biotech's value...
BioCentury | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BioCentury | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
Items per page:
1 - 10 of 257